Product logins

Find logins to all Clarivate products below.


Gout – Current Treatment – Treatment Algorithms: Claims Data Analysis – Gout (US)

Gout is a form of inflammatory arthritis caused by sustained hyperuricemia, or elevated serum uric acid (sUA) levels. This condition manifests through sudden and intense gout flares, causing significant discomfort. The therapeutic approach for acute flares differs from chronic gout management, and it is not the focus of this analysis. Chronic treatment aims to prevent recurrent gout attacks and limit joint damage by lowering sUA levels. Xanthine oxidase inhibitors (XOIs), especially the widely prescribed generic allopurinol, form the cornerstone of chronic gout treatment. For later lines of therapy, pegloticase (Krystexxa), a highly efficacious biological agent, is utilized. This report provides valuable insights into the use of these treatments in patients with newly diagnosed or recently treated chronic gout.

Questions answered

  • What patient shares do key therapies and brands garner by line of therapy in newly diagnosed chronic gout patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed chronic gout patients?
  • How has pegloticase been integrated into the treatment algorithm, and what is its source of business?
  • What percentage of chronic gout patients receive drug therapy within 365 of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within 365 of diagnosis?
  • What percentage of chronic gout patients are treated with monotherapy vs. combination therapy? What are the most used combinations?
  • What are the product-level compliance and persistency rates among drug-treated patients?

Product description

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, enabling you to:

  • Understand patient flow between lines of therapy.
  • Evaluate your brand share against competitors.
  • Accurately assess your source of business.
  • Quantify opportunities at different stages of the treatment algorithm.

Product enhancement

Treatment Algorithms: Claims Data Analysis leverages Clarivate’s proprietary Real-World Data, which brings larger patient samples, broader payer coverage, and faster availability for more robust and timely analyses. Additionally, we include new patient demographic analyses: age, gender, ethnicity, and region.

Related Market Assessment Reports

Report
Systemic Lupus Erythematosus – Access & Reimbursement – Access & Reimbursement – Systemic Lupus Erythematosus (US)
The U.S. systemic lupus erythematosus (SLE) therapy market is largely genericized and off-label. With the exception of GSK’s Benlysta, the firstagents approved for the indication in almost 60…
Report
Diabetic Macular Edema / Diabetic Retinopathy – Landscape & Forecast – Disease Landscape & Forecast (G7)
Diabetic macular edema (DME), a complication of diabetic retinopathy (DR), develops as a result of persistently elevated blood sugar levels and can lead to vision loss or blindness if left…
Report
Heart Failure – Current Treatment – Treatment Algorithms: Claims Data Analysis – Heart Failure with Reduced Ejection Fraction (US)
Heart failure with reduced ejection fraction (HFrEF) occurs when the left ventricular ejection fraction (LVEF) is 40% or less. Drug treatment for HFrEF is well established and supported by…
Report
Heart Failure – Current Treatment – Treatment Algorithms: Claims Data Analysis – Heart Failure with Preserved Ejection Fraction (US)
Heart failure with preserved ejection fraction (HFpEF) occurs when the left ventricular ejection fraction (LVEF) is 50% or more. Even though physicians’ understanding of the disease’s…
Report
Membranous Nephropathy – Landscape & Forecast – Disease Landscape & Forecast (G7)
Primary membranous nephropathy (pMN), the most common type of MN, is a rare autoantibody-mediated autoimmune kidney disease. Although it is one of the leading causes of nephrotic syndrome in…